Annual SG&A
$887.60 M
+$134.90 M+17.92%
31 December 2023
Summary:
Neurocrine Biosciences annual selling, general & administrative expenses is currently $887.60 million, with the most recent change of +$134.90 million (+17.92%) on 31 December 2023. During the last 3 years, it has risen by +$454.30 million (+104.85%). NBIX annual SG&A is now at all-time high.NBIX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$234.30 M
-$7.70 M-3.18%
30 September 2024
Summary:
Neurocrine Biosciences quarterly selling, general & administrative expenses is currently $234.30 million, with the most recent change of -$7.70 million (-3.18%) on 30 September 2024. Over the past year, it has increased by +$30.10 million (+14.74%). NBIX quarterly SG&A is now -3.62% below its all-time high of $243.10 million, reached on 31 March 2024.NBIX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$238.40 M
+$385.90 M+61.81%
30 September 2024
Summary:
Neurocrine Biosciences TTM selling, general & administrative expenses is currently -$238.40 million, with the most recent change of +$385.90 million (+61.81%) on 30 September 2024. Over the past year, it has dropped by -$1.09 billion (-127.99%). NBIX TTM SG&A is now -1399.37% below its all-time high of $938.30 million, reached on 30 September 2024.NBIX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.9% | +14.7% | -128.0% |
| 3 y3 years | +104.8% | +51.5% | -144.7% |
| 5 y5 years | +256.6% | +177.3% | -174.1% |
NBIX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +104.8% | -3.6% | +51.5% | at high | +91.2% |
| 5 y | 5 years | at high | +256.6% | -3.6% | +177.3% | at high | +95.1% |
| alltime | all time | at high | >+9999.0% | -3.6% | >+9999.0% | -1399.4% | +95.1% |
Neurocrine Biosciences Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $234.30 M(-3.2%) | $938.30 M(+3.3%) |
| June 2024 | - | $242.00 M(-0.5%) | $908.20 M(+2.3%) |
| Mar 2024 | - | $243.10 M(+11.1%) | $888.00 M(+0.0%) |
| Dec 2023 | $887.60 M(+17.9%) | $218.90 M(+7.2%) | $887.60 M(+4.2%) |
| Sept 2023 | - | $204.20 M(-7.9%) | $851.60 M(+2.1%) |
| June 2023 | - | $221.80 M(-8.6%) | $833.70 M(+4.9%) |
| Mar 2023 | - | $242.70 M(+32.7%) | $794.70 M(+5.6%) |
| Dec 2022 | $752.70 M(+29.0%) | $182.90 M(-1.8%) | $752.70 M(+3.6%) |
| Sept 2022 | - | $186.30 M(+1.9%) | $726.30 M(+4.6%) |
| June 2022 | - | $182.80 M(-8.9%) | $694.60 M(+6.0%) |
| Mar 2022 | - | $200.70 M(+28.2%) | $655.00 M(+12.3%) |
| Dec 2021 | $583.30 M(+34.6%) | $156.50 M(+1.2%) | $583.30 M(+9.4%) |
| Sept 2021 | - | $154.60 M(+8.0%) | $533.30 M(+8.6%) |
| June 2021 | - | $143.20 M(+11.0%) | $491.20 M(+10.5%) |
| Mar 2021 | - | $129.00 M(+21.1%) | $444.50 M(+2.6%) |
| Dec 2020 | $433.30 M(+22.4%) | $106.50 M(-5.3%) | $433.30 M(+1.2%) |
| Sept 2020 | - | $112.50 M(+16.6%) | $428.10 M(+7.0%) |
| June 2020 | - | $96.50 M(-18.1%) | $400.10 M(+4.1%) |
| Mar 2020 | - | $117.80 M(+16.3%) | $384.40 M(+8.6%) |
| Dec 2019 | $354.10 M(+42.3%) | $101.30 M(+19.9%) | $354.10 M(+10.1%) |
| Sept 2019 | - | $84.50 M(+4.6%) | $321.75 M(+8.1%) |
| June 2019 | - | $80.80 M(-7.7%) | $297.65 M(+7.2%) |
| Mar 2019 | - | $87.50 M(+26.9%) | $277.76 M(+11.6%) |
| Dec 2018 | $248.90 M(+46.5%) | $68.95 M(+14.2%) | $248.90 M(+5.3%) |
| Sept 2018 | - | $60.40 M(-0.8%) | $236.26 M(+7.5%) |
| June 2018 | - | $60.91 M(+3.9%) | $219.73 M(+9.6%) |
| Mar 2018 | - | $58.64 M(+4.1%) | $200.49 M(+18.0%) |
| Dec 2017 | $169.91 M(+149.6%) | $56.31 M(+28.3%) | $169.91 M(+23.8%) |
| Sept 2017 | - | $43.87 M(+5.3%) | $137.26 M(+23.8%) |
| June 2017 | - | $41.67 M(+48.6%) | $110.89 M(+31.7%) |
| Mar 2017 | - | $28.05 M(+18.5%) | $84.18 M(+23.6%) |
| Dec 2016 | $68.08 M(+109.6%) | $23.67 M(+35.3%) | $68.08 M(+27.6%) |
| Sept 2016 | - | $17.49 M(+16.9%) | $53.35 M(+12.8%) |
| June 2016 | - | $14.96 M(+25.2%) | $47.31 M(+21.5%) |
| Mar 2016 | - | $11.95 M(+33.7%) | $38.95 M(+19.9%) |
| Dec 2015 | $32.48 M(+80.6%) | $8.94 M(-22.0%) | $32.48 M(+13.9%) |
| Sept 2015 | - | $11.46 M(+73.5%) | $28.51 M(+31.3%) |
| June 2015 | - | $6.60 M(+20.4%) | $21.72 M(+12.4%) |
| Mar 2015 | - | $5.48 M(+10.3%) | $19.32 M(+7.4%) |
| Dec 2014 | $17.99 M(+34.7%) | $4.97 M(+6.6%) | $17.99 M(+10.0%) |
| Sept 2014 | - | $4.66 M(+11.0%) | $16.36 M(+9.5%) |
| June 2014 | - | $4.20 M(+1.1%) | $14.94 M(+5.9%) |
| Mar 2014 | - | $4.15 M(+24.3%) | $14.11 M(+5.7%) |
| Dec 2013 | $13.35 M(-0.7%) | $3.34 M(+3.0%) | $13.35 M(+0.2%) |
| Sept 2013 | - | $3.25 M(-3.7%) | $13.32 M(-0.6%) |
| June 2013 | - | $3.37 M(-0.6%) | $13.40 M(+1.8%) |
| Mar 2013 | - | $3.39 M(+2.4%) | $13.16 M(-2.1%) |
| Dec 2012 | $13.44 M(+7.9%) | $3.31 M(-0.4%) | $13.44 M(+5.8%) |
| Sept 2012 | - | $3.32 M(+6.2%) | $12.71 M(-3.2%) |
| June 2012 | - | $3.13 M(-14.7%) | $13.12 M(+1.9%) |
| Mar 2012 | - | $3.67 M(+42.3%) | $12.87 M(+3.3%) |
| Dec 2011 | $12.46 M(-6.1%) | $2.58 M(-31.0%) | $12.46 M(-2.7%) |
| Sept 2011 | - | $3.74 M(+29.6%) | $12.80 M(-0.1%) |
| June 2011 | - | $2.88 M(-11.4%) | $12.82 M(-2.8%) |
| Mar 2011 | - | $3.26 M(+11.4%) | $13.18 M(-0.7%) |
| Dec 2010 | $13.27 M | $2.92 M(-22.2%) | $13.27 M(-29.0%) |
| Sept 2010 | - | $3.75 M(+15.5%) | $18.71 M(+4.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $3.25 M(-2.9%) | $17.92 M(-8.1%) |
| Mar 2010 | - | $3.35 M(-60.0%) | $19.50 M(-4.2%) |
| Dec 2009 | $20.34 M(-39.6%) | $8.36 M(+181.7%) | $20.34 M(-30.4%) |
| Sept 2009 | - | $2.97 M(-38.6%) | $29.24 M(-1.7%) |
| June 2009 | - | $4.83 M(+15.1%) | $29.75 M(+0.5%) |
| Mar 2009 | - | $4.20 M(-75.7%) | $29.59 M(-12.1%) |
| Dec 2008 | $33.68 M(-10.1%) | $17.25 M(+397.0%) | $33.68 M(+23.8%) |
| Sept 2008 | - | $3.47 M(-25.6%) | $27.21 M(-18.3%) |
| June 2008 | - | $4.67 M(-43.7%) | $33.31 M(-11.1%) |
| Mar 2008 | - | $8.29 M(-23.2%) | $37.45 M(-0.1%) |
| Dec 2007 | $37.48 M(-31.7%) | $10.79 M(+12.7%) | $37.48 M(+10.9%) |
| Sept 2007 | - | $9.57 M(+8.7%) | $33.79 M(-16.1%) |
| June 2007 | - | $8.81 M(+5.9%) | $40.27 M(-8.2%) |
| Mar 2007 | - | $8.32 M(+17.2%) | $43.85 M(-20.1%) |
| Dec 2006 | $54.87 M(+29.6%) | $7.09 M(-55.8%) | $54.87 M(-11.1%) |
| Sept 2006 | - | $16.05 M(+29.5%) | $61.72 M(+5.2%) |
| June 2006 | - | $12.40 M(-35.9%) | $58.67 M(+4.7%) |
| Mar 2006 | - | $19.34 M(+38.7%) | $56.06 M(+32.4%) |
| Dec 2005 | $42.33 M(+88.6%) | $13.94 M(+7.3%) | $42.33 M(+22.1%) |
| Sept 2005 | - | $13.00 M(+32.8%) | $34.66 M(+27.9%) |
| June 2005 | - | $9.79 M(+74.5%) | $27.09 M(+19.0%) |
| Mar 2005 | - | $5.61 M(-10.5%) | $22.77 M(+1.4%) |
| Dec 2004 | $22.44 M(+9.0%) | $6.26 M(+15.4%) | $22.44 M(+3.9%) |
| Sept 2004 | - | $5.43 M(-0.8%) | $21.60 M(+0.6%) |
| June 2004 | - | $5.47 M(+3.5%) | $21.47 M(+1.6%) |
| Mar 2004 | - | $5.28 M(-2.5%) | $21.13 M(+2.6%) |
| Dec 2003 | $20.59 M(+61.9%) | $5.42 M(+2.3%) | $20.59 M(+9.8%) |
| Sept 2003 | - | $5.30 M(+3.1%) | $18.76 M(+12.2%) |
| June 2003 | - | $5.13 M(+8.2%) | $16.72 M(+13.5%) |
| Mar 2003 | - | $4.74 M(+32.3%) | $14.73 M(+15.8%) |
| Dec 2002 | $12.72 M(+17.2%) | $3.59 M(+10.2%) | $12.72 M(+0.3%) |
| Sept 2002 | - | $3.25 M(+3.2%) | $12.69 M(+10.3%) |
| June 2002 | - | $3.15 M(+15.4%) | $11.51 M(+2.6%) |
| Mar 2002 | - | $2.73 M(-23.1%) | $11.21 M(+3.3%) |
| Dec 2001 | $10.86 M(+9.0%) | $3.55 M(+71.4%) | $10.86 M(+5.0%) |
| Sept 2001 | - | $2.07 M(-27.4%) | $10.34 M(-4.0%) |
| June 2001 | - | $2.85 M(+20.1%) | $10.77 M(+6.6%) |
| Mar 2001 | - | $2.38 M(-21.6%) | $10.11 M(+1.4%) |
| Dec 2000 | $9.96 M(+32.8%) | $3.03 M(+20.8%) | $9.96 M(+12.8%) |
| Sept 2000 | - | $2.51 M(+14.7%) | $8.83 M(+7.4%) |
| June 2000 | - | $2.19 M(-2.0%) | $8.22 M(+2.3%) |
| Mar 2000 | - | $2.23 M(+17.5%) | $8.03 M(+7.1%) |
| Dec 1999 | $7.50 M(+13.6%) | $1.90 M(0.0%) | $7.50 M(0.0%) |
| Sept 1999 | - | $1.90 M(-5.0%) | $7.50 M(+1.4%) |
| June 1999 | - | $2.00 M(+17.6%) | $7.40 M(+10.4%) |
| Mar 1999 | - | $1.70 M(-10.5%) | $6.70 M(+3.1%) |
| Dec 1998 | $6.60 M(+15.8%) | $1.90 M(+5.6%) | $6.50 M(+4.8%) |
| Sept 1998 | - | $1.80 M(+38.5%) | $6.20 M(+3.3%) |
| June 1998 | - | $1.30 M(-13.3%) | $6.00 M(0.0%) |
| Mar 1998 | - | $1.50 M(-6.3%) | $6.00 M(+7.1%) |
| Dec 1997 | $5.70 M(+54.1%) | $1.60 M(0.0%) | $5.60 M(-1.8%) |
| Sept 1997 | - | $1.60 M(+23.1%) | $5.70 M(+18.8%) |
| June 1997 | - | $1.30 M(+18.2%) | $4.80 M(+14.3%) |
| Mar 1997 | - | $1.10 M(-35.3%) | $4.20 M(+13.5%) |
| Dec 1996 | $3.70 M | $1.70 M(+142.9%) | $3.70 M(+85.0%) |
| Sept 1996 | - | $700.00 K(0.0%) | $2.00 M(+53.8%) |
| June 1996 | - | $700.00 K(+16.7%) | $1.30 M(+116.7%) |
| Mar 1996 | - | $600.00 K | $600.00 K |
FAQ
- What is Neurocrine Biosciences annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual SG&A year-on-year change?
- What is Neurocrine Biosciences quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly SG&A year-on-year change?
- What is Neurocrine Biosciences TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM SG&A year-on-year change?
What is Neurocrine Biosciences annual selling, general & administrative expenses?
The current annual SG&A of NBIX is $887.60 M
What is the all time high annual SG&A for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual selling, general & administrative expenses is $887.60 M
What is Neurocrine Biosciences annual SG&A year-on-year change?
Over the past year, NBIX annual selling, general & administrative expenses has changed by +$134.90 M (+17.92%)
What is Neurocrine Biosciences quarterly selling, general & administrative expenses?
The current quarterly SG&A of NBIX is $234.30 M
What is the all time high quarterly SG&A for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly selling, general & administrative expenses is $243.10 M
What is Neurocrine Biosciences quarterly SG&A year-on-year change?
Over the past year, NBIX quarterly selling, general & administrative expenses has changed by +$30.10 M (+14.74%)
What is Neurocrine Biosciences TTM selling, general & administrative expenses?
The current TTM SG&A of NBIX is -$238.40 M
What is the all time high TTM SG&A for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM selling, general & administrative expenses is $938.30 M
What is Neurocrine Biosciences TTM SG&A year-on-year change?
Over the past year, NBIX TTM selling, general & administrative expenses has changed by -$1.09 B (-127.99%)